TrialCurvePANTHER: reconstructed Kaplan–Meier curves
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Reg Health Eur. 2024 Dec 3;49:101162. doi: 10.1016/j.lanepe.2024.101162 |
|---|---|
| DOI | 10.1016/j.lanepe.2024.101162 |
| Registry | NCT00798070 |
| Phase | Phase 3 |
| Conditions | Breast Cancer |
| Interventions | dtEC→dtT, FEC→T |
| Sponsor | Karolinska University Hospital |
| Enrolment | 2017 |
| Source licence | Figure published under CC BY 4.0 |
Breast cancer recurrence-free survival events (cumulative incidence) — Luminal (hormone receptor positive, HER2-negative)
From figure panel A · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 3 years: FEC/D 8%; tDD EC/D 5%. Hazard ratio tDD EC/D vs FEC/D 0.82 (95% CI 0.64–1.06).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| FEC/D | 686 | 129 | not reached |
| tDD EC/D | 700 | 108 | not reached |
- tDD EC/D vs FEC/D: reconstructed HR 0.82 (95% CI 0.64–1.06)
Cumulative incidence (reconstructed)
| Time | FEC/D | tDD EC/D |
|---|---|---|
| 1 yr | 1.3% | 0.6% |
| 2 yr | 3.3% | 2.1% |
| 3 yr | 7.6% | 4.6% |
| 5 yr | 12.3% | 8.5% |
| 7 yr | 15.6% | 12.5% |
| 10 yr | 21.0% | 18.1% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.83, reconstructed 0.822 pass
Breast cancer recurrence-free survival events (cumulative incidence) — HER2-positive
From figure panel B · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 3 years: FEC/D 12%; tDD EC/D 9%. Hazard ratio tDD EC/D vs FEC/D 0.51 (95% CI 0.29–0.91).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| FEC/D | 182 | 36 | not reached |
| tDD EC/D | 160 | 17 | not reached |
- tDD EC/D vs FEC/D: reconstructed HR 0.51 (95% CI 0.29–0.91)
Cumulative incidence (reconstructed)
| Time | FEC/D | tDD EC/D |
|---|---|---|
| 1 yr | 1.7% | 2.5% |
| 2 yr | 6.8% | 5.7% |
| 3 yr | 12.0% | 9.0% |
| 5 yr | 15.0% | 11.0% |
| 7 yr | 18.2% | 11.0% |
| 10 yr | 21.8% | 11.0% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.53, reconstructed 0.51 pass
Breast cancer recurrence-free survival events (cumulative incidence) — Triple negative
From figure panel C · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 3 years: FEC/D 23%; tDD EC/D 20%. Hazard ratio tDD EC/D vs FEC/D 0.97 (95% CI 0.62–1.51).
| Arm | N | Events | Median (Years) |
|---|---|---|---|
| FEC/D | 133 | 39 | not reached |
| tDD EC/D | 140 | 40 | not reached |
- tDD EC/D vs FEC/D: reconstructed HR 0.97 (95% CI 0.62–1.51)
Cumulative incidence (reconstructed)
| Time | FEC/D | tDD EC/D |
|---|---|---|
| 1 yr | 9.1% | 9.4% |
| 2 yr | 19.7% | 16.6% |
| 3 yr | 22.8% | 19.6% |
| 5 yr | 27.5% | 23.4% |
| 7 yr | 30.0% | 26.7% |
| 10 yr | 30.0% | 30.5% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.02, reconstructed 1.03 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- PEONY: Disease-free survival (DFS); Event-free survival (EFS)
- PATHWAY: Overall survival; Progression-free survival by blinded independent central review; Progres
- ACE-Breast-02: Overall survival; Progression-free survival assessed by BICR; Progression-free survival as
- Culmerciclib + fulvestrant in HR+/HER2− breast cancer: Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials